8-KShareholder Matters

ELI LILLY & Co 8-K Report, Shareholder Vote Results (May 6, 2014)

Filed May 6, 2014For Securities:LLY

Summary

Eli Lilly and Company (LLY) filed an 8-K on May 5, 2014, reporting the results of its annual meeting of shareholders held on May 4, 2014. The primary focus of the filing is the voting outcomes on key corporate matters, providing shareholders with transparency on the company's governance and operational decisions. The results indicate strong shareholder support for the company's board of directors and its proposed executive compensation, as well as the ratification of its independent auditor. This report is significant for investors as it reflects the confidence of the shareholder base in the current leadership and the company's direction. The overwhelming approval of director nominees and the advisory vote on executive compensation suggest a stable governance environment. Furthermore, the ratification of Ernst & Young as the principal independent auditor reinforces the company's commitment to financial transparency and accountability.

Key Highlights

  • 1Five director nominees were elected to serve three-year terms ending in 2017, with substantial 'For' votes for all nominees.
  • 2The appointment of Ernst & Young as the principal independent auditor was ratified by a significant majority of shareholders.
  • 3Shareholders approved, on an advisory basis, the compensation paid to named executive officers.
  • 4The voting results demonstrate strong shareholder support for the company's board and its executive compensation practices.
  • 5A total of 1,119,757,288 shares of common stock were issued and outstanding as of the meeting's record date.
  • 6The filing includes detailed vote counts for each director nominee, auditor ratification, and the advisory executive compensation vote.

Frequently Asked Questions

This 8-K filing was primarily to report the outcomes of Eli Lilly and Company's annual meeting of shareholders, specifically detailing the voting results on the election of directors, the ratification of the independent auditor, and an advisory vote on executive compensation.

Yes, all five nominees for director were elected to serve three-year terms ending in 2017. The vote counts show a very high level of support for each nominee.

Yes, the appointment of Ernst & Young as Eli Lilly's principal independent auditor was ratified by shareholders with a substantial majority of 'For' votes.

Shareholders approved, on an advisory basis, the compensation paid to the company's named executive officers. The 'For' votes significantly outnumbered the 'Against' and 'Abstain' votes.